ASX rallies back to close higher
The ASX rallied to close 0.43% higher. Australia’s ETF industry has hit an all-time high. And there’s movement in the BHP boardroom.
Stockhead
ASX companies waiting for US FDA kick-off
A large number of Australian biotechs are waiting for US FDA product approval – or are on the cusp of lodging an application.
Vitura swoops on medical dope telehealth platform
Backed by Rich Lister Prof Khalil (Charlie) Shahin, Vitura Health is paying $5.9 million for private medical cannabis telehealth provider Candor Medical.
Gold hits stun in 160% Caprice gain
Caprice shares flew through the roof on impressive Phase 1 gold drilling results at the Island gold asset in WA.
More Stories
Why Trumps’ tariffs risk backfiring
Nigel Green takes a look at Trump’s hardline economic policies, and why China could ultimate benefit from his adversarial powerplays.
Trump’s tariffs come for copper
Trump’s tariffs could shake up copper and iron ore, and investors need to watch out for risks ahead.
It’s not just gold, these stocks have legs too
Record prices have gold in favour, but Precision Funds Management’s Dermot Woods joins Stockhead to get creative with other value ASX stocks.
Chile’s copper forecasts lift optimism
Chile’s copper commission Cochilco forecast prices of US$4.25/lb for the red metal for the next two years as demand rises.
MM8 steps closer to Ravensthorpe development
Medallion Metals is closer to securing EPBC approval, the key outstanding required to develop its 1.6Moz Ravensthorpe gold project.
Vital Signs: Wellnex Life
Nadine McGrath chats to Zack Bozinovski from Wellnex Life to learn more about the company’s health and wellness offerings.
Gold, iron ore lift in January
Gold hit a new record high and iron ore weathered a Trumpian storm, but lithium, coal and uranium battled in January.
ADX’s Italian licence has big gas potential
ADX Energy’s new Italian licence benefits from a pro-development government and the potential to host rich gas resources on Europe’s doorstep.
Gold shines as ASX nears record
The ASX has closed up over 1.2%, News Corp’s killing it, and Nissan is ditching Honda for a US electric car buddy.
Percheron closes the chapter on trial disaster
Percheron Therapeutics says it will abandon its lead drug candidate altogether, following December’s Duchenne muscular dystrophy trial flop.
Original URL: https://www.goldcoastbulletin.com.au/business/stockhead/page/10